Literature DB >> 2112528

Cyclophosphamide-dependent lymph node modification in lymph node metastasis of MM48 tumor cells in syngeneic mice.

K Yoshida1, T Tachibana.   

Abstract

We investigated the role of immunosuppressive activity induced in the regional lymph nodes (RLN, popliteal lymph nodes) in the establishment of lymph node metastasis by cyclophosphamide (CY) administration. The CY treatment led to the elimination of suppressive activity with the appearance of positive immune responses, and the inhibition of lymph node metastasis of MM48 tumor cells. In CY-treated mice, the removal of RLN together with the primary tumor lowered the survival rate compared with the mice in which the RLN remained intact. During 4 days after primary tumor resection, the proliferation of tumor cells in the RLN was significantly decreased in CY-treated mice. These results suggested that the induction of suppressive activity in the lymph node is closely associated with the establishment of lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112528      PMCID: PMC5918035          DOI: 10.1111/j.1349-7006.1990.tb02558.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


cyclophosphamide peritoneal exudate cells phosphate‐buffered saline regional lymph node (popliteal) minimum essential medium
  15 in total

1.  The effect of removal of a "primary" tumor on the development of spontaneous metastases. I. Development of a standardized experimental technic.

Authors:  A S KETCHAM; H WEXLER; N MANTEL
Journal:  Cancer Res       Date:  1959-10       Impact factor: 12.701

2.  Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice.

Authors:  I Gresser; C Maury; M Tovey
Journal:  Eur J Cancer       Date:  1978-01       Impact factor: 9.162

3.  Growth of a local tumor exerts a specific inhibitory effect on progression of lung metastases.

Authors:  E Gorelik; S Segal; M Feldman
Journal:  Int J Cancer       Date:  1978-05-15       Impact factor: 7.396

4.  Tumor regression in tumor-bearing mice by inoculations of immunogenic somatic hybrid cells in combination with cyclophosphamide.

Authors:  T Tachibana; T Dei
Journal:  Tokai J Exp Clin Med       Date:  1983-12

5.  The effects of cyclophosphamide on in vitro cytotoxic responses to a syngeneic tumour.

Authors:  E J Hancock; D G Kilburn
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid.

Authors:  J K Youn; F Lacour; G Hue
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

7.  Suppressor pathways in tumor immunity: a requirement for Qa-1 positive tumor-bearer spleen T cells in suppression of the afferent immune response to tumor antigens.

Authors:  J J Mulé; T H Stanton; I Hellström; K E Hellström
Journal:  Int J Cancer       Date:  1981-09-15       Impact factor: 7.396

8.  Quantitative studies of translymphnodal passage of tumour cells naturally disseminated from a non immunogenic murine squamous carcinoma.

Authors:  H B Hewitt; E Blake
Journal:  Br J Cancer       Date:  1975-01       Impact factor: 7.640

9.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

10.  Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  1 in total

1.  Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells.

Authors:  K Yoshida; T Tachibana
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.